1. Home
  2. POWW vs IKT Comparison

POWW vs IKT Comparison

Compare POWW & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMMO Inc.

POWW

AMMO Inc.

HOLD

Current Price

$2.36

Market Cap

235.8M

Sector

Industrials

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.89

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POWW
IKT
Founded
1990
2008
Country
United States
United States
Employees
81
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.8M
220.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
POWW
IKT
Price
$2.36
$1.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$2.40
$5.00
AVG Volume (30 Days)
691.6K
570.6K
Earning Date
02-09-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.56
N/A
Revenue Next Year
$0.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.08
$1.33
52 Week High
$2.46
$2.26

Technical Indicators

Market Signals
Indicator
POWW
IKT
Relative Strength Index (RSI) 74.11 63.08
Support Level $1.94 $1.63
Resistance Level N/A $1.91
Average True Range (ATR) 0.10 0.08
MACD 0.03 0.03
Stochastic Oscillator 78.00 80.95

Price Performance

Historical Comparison
POWW
IKT

About POWW AMMO Inc.

Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: